• Home
  • Terms of Use
  • Privacy Policy
  • Disclosure
Saturday, June 25, 2022
  • Home
  • News
  • Business
  • Technology
    • Crytpocurrency
    • Gaming
    • Gadgets
  • Sports
  • Health
  • General
    • Business Services
  • Travel
  • Press Releases
  • Videos
No Result
View All Result
  • Home
  • News
  • Business
  • Technology
    • Crytpocurrency
    • Gaming
    • Gadgets
  • Sports
  • Health
  • General
    • Business Services
  • Travel
  • Press Releases
  • Videos
No Result
View All Result
Omicron b11529 Variant
No Result
View All Result
Home Omicron Variant

Study Explains The Structural Basis Of Higher ACE2 Binding Affinity Of Omicron Sub-Variants – News-Medical.Net

by NewsReporter
June 22, 2022
in Omicron Variant
Reading Time: 3 mins read
Share on FacebookShare on Twitter

A team of scientists from China has recently deciphered the structural basis of comparatively higher binding affinity of two Omicron sub-variants, namely B.1.1 and B.2, for human angiotensin-converting enzyme 2 (ACE2). The study has been published in the journal Cell. 

Study: Structural basis of human ACE2 higher binding affinity to currently circulating Omicron SARS-CoV-2 sub-variants BA.2 and BA.1.1. Image Credit: CROCOTHERY/Shutterstock 

Background

The omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the latest identified variant of concern (VOC) with a heavily mutated spike protein. During the initial phase of the global Omicron wave, four sub-variants emerged, namely B.1, B.1.1, B.2, and B.3. Preliminary studies have shown that the B.2 sub-variant has higher replication and transmission fitness than other circulating sub-variants.

The binding of the SARS-CoV-2 spike receptor-binding domain (RBD) to human ACE2 is a crucial step for viral entry. Compared to the original Omicron variant (prototype), the sub-variants contain 14-15 mutations in their spike RBDs. It has been observed previously that both prototype Omicron and B.1 sub-variant share a similar binding affinity for human ACE2.

In the current study, the scientists have investigated the binding affinities of B.1, B.1.1, B.2, and B.3 RBDs for human ACE2. In addition, they have evaluated the structural features responsible for diverse binding affinities of omicron sub-variants.

Human ACE2 binding affinities of Omicron sub-variants

The mutational analysis revealed that B.1 and B.1.1 have 15 and 16 mutations in their spike RBDs, respectively. The extra mutation in B.1.1 RBD is R346K. Among various sub-variants of omicron, B.1.1 is globally predominating, accounting for about 26% of the total Omicron genomes.

The surface plasmon resonance method was applied to determine the binding affinities of four Omicron sub-variants (B.1, B.1.1, B.2, and B.3), the prototype variant, and four known VOCs (alpha, beta, gamma, and delta) for human ACE2.

The findings revealed that compared to the prototype variant, B.1.1 has the highest affinity for human ACE2, followed by B.2, B.1, and B.3. The binding affinities of B.1 and B.3 were almost similar. Among previously circulating VOCs, the binding affinity of only the Alpha variant was equivalent to that of the B.1.1 Omicron sub-variant.

Structural analysis of RBD-ACE2 complex

The binding interface analysis was conducted between human ACE2 and RBDs of B.1.1, B.2, and B.3 sub-variants.

The findings revealed that the absence of G496S mutation in the B.2 RBD/human ACE2 binding interface is responsible for its higher ACE2 binding affinity than B.1. Further analysis revealed that the hydroxyl side chain of S496 forms more compact intra-chain hydrogen bonds within the B.1 RBD, reducing the inter-chain interactions between RBD and ACE2. This explains why the B.1 RBD with G496S mutation has a lower ACE2 binding affinity than the B.2 RBD, which lacks this mutation.   

The presence of R346K mutation in the B.1.1 RBD was responsible for its higher ACE2 binding affinity than B.1. Further analysis revealed that the R346K mutation severely affects the amino acid-amino acid interaction network at the RBD-ACE2 binding interface through long-distance alterations. These changes are responsible for the increased binding affinity of B.1.1 for human ACE2.

Study significance

The study compares human ACE2 binding affinities of different Omicron sub-variants and explains the structural basis of these variations. Specifically, the study highlights the significance of G496S and R346K RBD mutations in increasing ACE2 binding affinities of the B.2 and B.1.1 sub-variants, respectively, as compared to the B.1 sub-variant.

Several novel sub-variants of SARS-CoV-2 Omicron have been identified globally, including BA.2.12.1, B.4, and B.5. Of these sub-variants, BA.2.12.1 is rapidly spreading in the Northeast United States, and B.4 and B.5 are spreading dominantly in South Africa.

The study explains that despite being located outside of the spike receptor-binding motif, the R346K mutation can increase the binding affinity by altering interaction networks at the RBD-ACE2 interface via long-distance “conduction” interactions.

Journal reference:

  • Li, L. et al. (2022) “Structural basis of human ACE2 higher binding affinity to currently circulating Omicron SARS-CoV-2 sub-variants BA.2 and BA.1.1”, Cell. doi: 10.1016/j.cell.2022.06.023. https://www.sciencedirect.com/science/article/pii/S0092867422007280

Related Posts

covid-19-disease-severity-in-us-veterans-infected-during-omicron-and-delta-variant-predominant-periods-–-nature.com

COVID-19 Disease Severity In US Veterans Infected During Omicron And Delta Variant Predominant Periods – Nature.com

by NewsReporter
June 25, 2022
0

AbstractThe SARS-CoV-2 Omicron variant is thought to cause less severe disease among the general population, but disease severity among at-risk populations is unknown. We performed a retrospective analysis using a matched cohort of United States veterans to compare the disease severity of subjects infected during Omicron and Delta predominant periods...

covid-19-variant-shot-from-sanofi,-gsk-effective-against-omicron-–-the-wall-street-journal

Covid-19 Variant Shot From Sanofi, GSK Effective Against Omicron – The Wall Street Journal

by NewsReporter
June 25, 2022
0

LONDON—GSK PLC and Sanofi SA reported promising trial results for their Covid-19 vaccine that showed the shot—developed to target the Beta strain of the virus—was particularly effective against the Omicron variant.The two companies said Friday that in a trial involving 13,000 adults, the vaccine demonstrated efficacy of 64.7% against symptomatic...

the-next-covid-booster-shots-will-likely-be-updated-for-omicron-–-edmonton-journal

The Next COVID Booster Shots Will Likely Be Updated For Omicron – Edmonton Journal

by NewsReporter
June 25, 2022
0

Author of the article: A nurse inoculates a man with a booster dose of vaccine against COVID-19 on Feb. 15, 2022. Photo by ALFREDO ESTRELLA / AFP NEW YORK — COVID-19 vaccines this fall are likely to be based on the Omicron variant of the coronavirus rather than the original...

analysis:-the-next-covid-booster-shots-will-likely-be-updated-for-omicron-–-reuters.com

Analysis: The Next COVID Booster Shots Will Likely Be Updated For Omicron – Reuters.com

by NewsReporter
June 24, 2022
0

REUTERS/Hannah BeierRegister now for FREE unlimited access to Reuters.comNEW YORK (Reuters) - COVID-19 vaccines this fall are likely to be based on the Omicron variant of the coronavirus rather than the original strain, although some experts suggest they may only offer significant benefits for older and immunocompromised people.Moderna, Pfizer and...

BioMarin’s Hemophilia Gene Therapy Roctavian Wins Conditional EU Backing Amid FDA Delay – FiercePharma

by NewsReporter
June 24, 2022
0

Please enable cookies. We are checking your browser... www.fiercepharma.com Why do I have to complete a CAPTCHA? Completing the CAPTCHA proves you are a human and gives you temporary access to the web property. What can I do to prevent this in the future? If you are on a personal...

Amid M&A Rumors, Merck And Seagen Set To Meet: WSJ – FiercePharma

by NewsReporter
June 24, 2022
0

Why do I have to complete a CAPTCHA? Completing the CAPTCHA proves you are a human and gives you temporary access to the web property. What can I do to prevent this in the future? If you are on a personal connection, like at home, you can run an anti-virus...

Omicron b11529 Variant

© 2021

Navigate Site

  • Home
  • Terms of Use
  • Privacy Policy
  • Disclosure

Follow Us

No Result
View All Result
  • Home

© 2021